Abstract | PURPOSE: METHODS: RESULTS: Previous therapies included photodynamic therapy, posterior sub-Tenon's triamcinolone, oral prednisolone, and intravitreal triamcinolone. Ten eyes in 10 patients underwent a mean of 1.9 ± 1.3 (± standard deviation) injections of antivascular endothelial growth factor (range, 1-5). All 10 patients had a follow-up review of at least 6 months (median, 12.5 ± 9.2 standard deviation; range, 6-34 months). Nine eyes either maintained or improved vision by at least 1 line on the logarithmic of the minimal angle of resolution calculated equivalent chart at least 6 months after the start of treatment with antivascular endothelial growth factor therapy. No ocular or systemic complications were observed. CONCLUSION:
|
Authors | Victor Menezo, Fiona Cuthbertson, Susan M Downes |
Journal | Retina (Philadelphia, Pa.)
(Retina)
Vol. 30
Issue 9
Pg. 1400-4
(Oct 2010)
ISSN: 1539-2864 [Electronic] United States |
PMID | 20224465
(Publication Type: Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Ranibizumab
|
Topics |
- Adult
- Angiogenesis Inhibitors
(administration & dosage, therapeutic use)
- Antibodies, Monoclonal
(administration & dosage, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Choroid Diseases
(complications)
- Choroidal Neovascularization
(drug therapy, etiology, physiopathology)
- Female
- Fluorescein Angiography
- Humans
- Intravitreal Injections
- Male
- Middle Aged
- Ranibizumab
- Retrospective Studies
- Tomography, Optical Coherence
- Visual Acuity
(physiology)
|